Trial of Intravenous Immune Globulin in Dermatomyositis.
作者信息
Werth Victoria P, Fiorentino David F, Vleugels Ruth Ann
机构信息
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Stanford University School of Medicine, Redwood City, CA.
出版信息
N Engl J Med. 2023 Jan 5;388(1):94. doi: 10.1056/NEJMc2214285.
Abstract
摘要
相似文献
1
Trial of Intravenous Immune Globulin in Dermatomyositis.
N Engl J Med. 2023 Jan 5;388(1):94. doi: 10.1056/NEJMc2214285.
2
Trial of Intravenous Immune Globulin in Dermatomyositis. Reply.
N Engl J Med. 2023 Jan 5;388(1):94-95. doi: 10.1056/NEJMc2214285.
3
[Physiopathology of polymyositis and dermatomyositis, mechanism of action of intravenous immunoglobulins].
Rev Med Interne. 2004 Dec;25 Spec No 3:10-2.
4
Intravenous Immune Globulin Therapy in Dermatomyositis.
N Engl J Med. 2022 Oct 6;387(14):1320-1321. doi: 10.1056/NEJMe2209117.
5
In adults with active dermatomyositis, IV immune globulin improved treatment response at 16 wk vs. placebo.
Ann Intern Med. 2023 Feb;176(2):JC22. doi: 10.7326/J22-0111. Epub 2023 Feb 7.
6
Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease.
J Clin Immunol. 1995 Nov;15(6 Suppl):70S-75S. doi: 10.1007/BF01540896.
7
Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy.
Obstet Gynecol. 2007 Feb;109(2 Pt2):561-3. doi: 10.1097/01.AOG.0000253244.45837.7c.
8
A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.
N Engl J Med. 1993 Dec 30;329(27):1993-2000. doi: 10.1056/NEJM199312303292704.
9
Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin.
BMJ Case Rep. 2012 Aug 18;2012:bcr2012006629. doi: 10.1136/bcr-2012-006629.
10
Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis.
Clin Exp Dermatol. 1995 Mar;20(2):164-7. doi: 10.1111/j.1365-2230.1995.tb02675.x.
引用本文的文献
1
Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review.
Rheumatology (Oxford). 2025 Jun 1;64(6):3288-3302. doi: 10.1093/rheumatology/keaf116.
2
Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives.
Ann Dermatol. 2024 Oct;36(5):257-265. doi: 10.5021/ad.24.022.
本文引用的文献
1
Trial of Intravenous Immune Globulin in Dermatomyositis.
N Engl J Med. 2022 Oct 6;387(14):1264-1278. doi: 10.1056/NEJMoa2117912.
2
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.
J Invest Dermatol. 2022 Oct;142(10):2651-2659.e1. doi: 10.1016/j.jid.2022.03.029. Epub 2022 Apr 29.
3
Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis.
Br J Dermatol. 2020 Apr;182(4):949-954. doi: 10.1111/bjd.18223. Epub 2019 Sep 8.
4
Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota.
Arch Dermatol. 2010 Jan;146(1):26-30. doi: 10.1001/archdermatol.2009.328.
5
Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument.
Br J Dermatol. 2010 Mar;162(3):669-73. doi: 10.1111/j.1365-2133.2009.09521.x. Epub 2009 Oct 26.
Zotero 插件